Literature DB >> 19528460

Overexpression of adenovirus-mediated p27kip1 lacking the Jab1-binding region enhances cytotoxicity and inhibits xenografted human cholangiocarcinoma growth.

Satoru Shiraso1, Yu Katayose, Kuniharu Yamamoto, Masamichi Mizuma, Shinichi Yabuuchi, Akira Oda, Toshiki Rikiyama, Tohru Onogawa, Hiroshi Yoshida, Hiroki Hayashi, Hideo Ohtsuka, Fuyuhiko Motoi, Shinichi Egawa, Junya Kato, Michiaki Unno.   

Abstract

The cyclin-dependent kinase inhibitor (CDK1) p27(kip1) is a negative regulator of cell cycling and has antitumor effects. In our previous study, the recombinant adenovirus expressing wild-type p27(kip1) (Adp27-wt) induced cell cycle arrest and apoptosis, and proved that p27 is a tumor suppressor gene like p53. Another adenovirus vector expressing mutant p27(kip1) (Adp27-mt), which inhibited degradation by the ubiquitin-proteasome system, showed increased protein stability and caused a stronger induction of apoptosis. Recently, the p27(kip1) protein binding with Jab1 (Jun activating binding protein 1) was found to translocate from the nucleus into the cytosol, and then become degraded by the 26S proteasome system. The inhibition of nuclear-cytoplasmic translocation increases the protein stability of p27(kip1) and p27(kip1) with a deletion of the Jab1-binding region (p27-jab-d) is not translocated and not degraded. Therefore, a new recombinant adenovirus (Adp27-jab-d) expressing p27-jab-d was made which was able to induce greater cytotoxicity. Adp27-jab-d inhibited the growth of human cholangiocarcinoma cell line (TFK-1) cells in vitro at 3.3 times (IC(50)) lower concentration than Adp27-wt. Moreover, in a xenografted severe combined immuno-deficient (SCID) mouse model injected with TFK-1 cells in the subcutaneous tissue, treatment by intratumor injection of Adp27-jab-d once a day for 3 days after the tumor was established, inhibited tumor growth more strongly than Adp27-wt or Adp27-mt and even induced tumor regression. However, the flow cytometric TUNEL assay showed little enhancement of apoptosis. Adp27-jab-d was thought to induce not only apoptosis but also necrosis, which was due to a specific effect of the Adp27-jab-d. Thus, by enhancing the cytotoxicity through inhibiting the translocaton of p27(kip1), p27(kip1) lacking the Jab1-binding region might be useful for cancer therapy. The control protein localization might also be a new target not only for cancer treatment, but also other diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528460

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.

Authors:  Samuele De Minicis; Tatiana Kisseleva; Heather Francis; Gianluca Svegliati Baroni; Antonio Benedetti; David Brenner; Domenico Alvaro; Gianfranco Alpini; Marco Marzioni
Journal:  Dig Liver Dis       Date:  2012-11-22       Impact factor: 4.088

2.  Skp2-RNAi suppresses proliferation and migration of gallbladder carcinoma cells by enhancing p27 expression.

Authors:  Bin Zhang; Lin-Hua Ji; Wei Liu; Gang Zhao; Zhi-Yong Wu
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

3.  BMP-2 overexpression augments vascular smooth muscle cell motility by upregulating myosin Va via Erk signaling.

Authors:  Ming Zhang; Min Yang; Li-ping Liu; Wayne Bond Lau; Hai Gao; Man-kun Xin; Li-Xiao Su; Jian Wang; Shu-Juan Cheng; Qian Fan; Jing-Hua Liu
Journal:  Oxid Med Cell Longev       Date:  2014-03-20       Impact factor: 6.543

4.  CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.

Authors:  Jian Luo; Yongjun Chen; Qiang Li; Bing Wang; Yanqiong Zhou; Hongzhen Lan
Journal:  Int J Mol Med       Date:  2016-06-07       Impact factor: 4.101

5.  Sumoylation in p27kip1 via RanBP2 promotes cancer cell growth in cholangiocarcinoma cell line QBC939.

Authors:  Jun Yang; Yan Liu; Bing Wang; Hongzhen Lan; Ying Liu; Fei Chen; Ju Zhang; Jian Luo
Journal:  BMC Mol Biol       Date:  2017-09-07       Impact factor: 2.946

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.